Back to Stakeholders
Care Delivery & Psychedelic FacilitationPsychedelic Healthcare Implementation
Care Delivery & Psychedelic FacilitationPsychedelic Healthcare ImplementationHealth Economists
Care Delivery & Psychedelic FacilitationPsychedelic Healthcare ImplementationPayer & Reimbursement Stakeholders

Oregon Health Authority Pharmacy & Therapeutics Committee

Oregon's Medicaid pharmacy evidence and recommendation body, with public meeting documentation used for treatment access and utilization policy decisions, including explicit Spravato/esketamine prior-authorization content.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

HTA / Value Assessment Body

Jurisdiction

Subnational / State-Level

Coverage

1 country

Last Verified

Apr 11, 2026

Focus Areas

HTA Evidence AppraisalCoverage Policy DesignFormulary & Access Criteria

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessCost-EffectivenessBudget Impact

Market Access Notes

Oregon P&T and OHA advisory packets include detailed prior-authorization criteria and evidence review content for Spravato/esketamine.

Verification

Verified

Psychedelic Focus

Explicit Psychedelic Focus

Engagement Status

Active

Verification Notes

Verified with explicit Spravato/esketamine sections in Oregon P&T and OHA MHCAG meeting packets.

Primary Access Link

Linked Stakeholders

Institute for Clinical and Economic Review (ICER)

Source Evidence

Oregon P&T Meeting Complete Packet (June 5, 2025)

https://www.orpdl.org/durm/meetings/meetingdocs/2025_06_05/finals/2025_06_05_PnT_Complete.pdf

OHA Mental Health Clinical Advisory Group Packet (Feb 1, 2024)

https://www.oregon.gov/oha/HPA/DSI-Pharmacy/MHCAGMeetingDocs/2024-02-01-MHCAG-Packet.pdf

Quick Facts

Website
Visit